CLINICAL_TRIALS
trial_result
· 2020-04-01
Clinical Trial Update: Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis [Phase 1]
Summary
Phase 1 trial update of oral ixazomib in adults with relapsed or refractory light chain amyloidosis has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Light-Chain Amyloidosis | Phase 1 | Status: COMPLETED | Results posted: 2020-04-01